Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

106
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
106
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

112
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
112
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.2K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.1K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.1K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

302
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
302
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.1K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to "Elimination diet and formula choice in the management of food protein-induced allergic proctocolitis (FPIAP)".

The journal of allergy and clinical immunology. In practice·2026
Same author

When IgE means more-and less-than allergy: Rethinking food sensitization in cardiovascular disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.

PloS one·2026
Same author

The story of aluminium containing vaccines is bigger than any one study.

BMJ (Clinical research ed.)·2026
Same author

Finding a Balance: Auricular Acupressure in the Allergy Clinic.

The journal of allergy and clinical immunology. In practice·2026
Same author

Balancing patient perspectives and evidence in food protein-induced enterocolitis syndrome (FPIES).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Related Experiment Video

Updated: Oct 10, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K

CSACI position statement: transition recommendations on existing epinephrine autoinjectors.

Lucy Dong Xuan Li1, Elissa M Abrams2, Elana Lavine3,4

  • 1Department of Paediatrics, Division of Clinical Immunology and Allergy, University of Toronto, Toronto, ON, Canada.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|December 14, 2021
PubMed
Summary

Epinephrine autoinjectors (EAI) are crucial for anaphylaxis treatment. Current guidelines suggest considering the 0.50 mg EAI for patients weighing 45 kg or more to avoid potential underdosing with the 0.30 mg EAI.

Keywords:
0.5 mg epinephrine autoinjectorAnaphylaxisCSACI position statementEpinephrine

More Related Videos

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:42

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

150
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

Related Experiment Videos

Last Updated: Oct 10, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K
Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:42

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

150
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

Area of Science:

  • Allergy and Immunology
  • Pharmacology
  • Emergency Medicine

Background:

  • Anaphylaxis is a severe allergic reaction requiring immediate treatment.
  • Epinephrine is the first-line therapy, typically given intramuscularly.
  • Canadian epinephrine autoinjectors (EAI) are available in 0.15 mg, 0.30 mg, and 0.50 mg doses.

Purpose of the Study:

  • To address the lack of comparative studies on 0.30 mg and 0.50 mg EAIs.
  • To evaluate potential underdosing with 0.30 mg EAIs in heavier patients.
  • To inform clinical practice regarding appropriate EAI selection based on weight.

Main Methods:

  • This study is a review of current guidelines and dosing recommendations.
  • Analysis of weight-based epinephrine dosing (0.01 mg/kg).
  • Consideration of available EAI strengths in Canada.

Main Results:

  • The 0.30 mg EAI may lead to underdosing in patients weighing over 30 kg.
  • The percentage of the recommended dose decreases as weight increases above 30 kg.
  • No published studies directly compare the clinical effectiveness of 0.30 mg and 0.50 mg EAIs.

Conclusions:

  • Physicians may consider the 0.50 mg EAI for patients weighing 45 kg or more.
  • Shared decision-making between physicians and patients is recommended for EAI selection.
  • Ensuring adequate epinephrine dosing is critical for managing anaphylaxis effectively.